| 3.39 -0.03 (-0.88%) | 10-27 14:20 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.11 | 1-year : | 5.88 |
| Resists | First : | 4.37 | Second : | 5.03 |
| Pivot price | 3.73  |
|||
| Supports | First : | 3.29 | Second : | 2.74 |
| MAs | MA(5) : | 3.56 |
MA(20) : | 3.9 |
| MA(100) : | 5.08 |
MA(250) : | 5.81 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 13.4 |
D(3) : | 19.8 |
| RSI | RSI(14): 34.7 | |||
| 52-week | High : | 9.82 | Low : | 3.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VRCA ] has closed above bottom band by 20.6%. Bollinger Bands are 3.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.56 - 3.58 | 3.58 - 3.6 |
| Low: | 3.34 - 3.37 | 3.37 - 3.39 |
| Close: | 3.38 - 3.42 | 3.42 - 3.45 |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Fri, 23 Oct 2026
Verrica Pharmaceuticals Inc. Estimates – NASDAQ:VRCA - TradingView
Wed, 14 Oct 2026
Verrica Pharmaceuticals Q2 2026 Earnings Call Transcript - Benzinga
Thu, 01 Oct 2026
Lake Street Keeps Their Buy Rating on Verrica Pharmaceuticals (VRCA) - The Globe and Mail
Wed, 30 Sep 2026
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences - GlobeNewswire
Fri, 28 Aug 2026
Technical Analysis on One NASDAQ- Listed Pharmaceuticals Stock: VRCA - Kalkine
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 49 (%) |
| Held by Institutions | 27.1 (%) |
| Shares Short | 196 (K) |
| Shares Short P.Month | 223 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | -102.9 % |
| Operating Margin | -194.5 % |
| Return on Assets (ttm) | -44 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -54 % |
| Gross Profit (p.s.) | 0.66 |
| Sales Per Share | 1.76 |
| EBITDA (p.s.) | -1.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -1.96 |
| PEG Ratio | 0 |
| Price to Book value | 13.68 |
| Price to Sales | 1.93 |
| Price to Cash Flow | -4.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|